Cargando…

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer

PURPOSE: To investigate the safety, activity, and potential biomarkers of response to olaparib and carboplatin combination in sporadic triple negative breast cancer (TNBC). EXPERIMENTAL DESIGN: Metastatic or recurrent TNBC patients with no germline BRCA mutation or with BRCAPro scores <10% and a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Jung-Min, Hays, John L., Chiou, Victoria L., Annunziata, Christina M., Swisher, Elizabeth M., Harrell, Maria I., Yu, Minshu, Gordon, Nicolas, Sissung, Tristan M., Ji, Jiuping, Figg, William D., Minasian, Lori, Lipkowitz, Stanley, Wood, Bradford J., Doroshow, James, Kohn, Elise C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668030/ https://www.ncbi.nlm.nih.gov/pubmed/29108297 http://dx.doi.org/10.18632/oncotarget.16577

Ejemplares similares

Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk
por: Lampert, Erika J., et al.
Publicado: (2019)

CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer
por: Lee, Jung-Min, et al.
Publicado: (2015)

Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions
por: Moon, D H, et al.
Publicado: (2013)

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first in class, proof-of-concept, single arm phase 2 study
por: Lee, Jung-Min, et al.
Publicado: (2018)

Pharmacogenomics Testing in Phase I Oncology Clinical Trials: Constructive Criticism Is Warranted
por: Sissung, Tristan M., et al.
Publicado: (2022)

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
por: Zimmer, Alexandra S., et al.
Publicado: (2019)

A Phase I dose‐escalation study of two cycles carboplatin‐olaparib followed by olaparib monotherapy in patients with advanced cancer
por: Geenen, Jill J. J., et al.
Publicado: (2021)

Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple-negative breast cancer cells
por: Zhao, Hui, et al.
Publicado: (2018)

Olaparib in the management of ovarian cancer
por: Bixel, Kristin, et al.
Publicado: (2015)

Precision medicine applications in prostate cancer
por: McCrea, Edel M., et al.
Publicado: (2018)

First-in-human phase 0 study of (111)In-CHX-A”-DTPA trastuzumab for HER2 tumor imaging
por: Kurdziel, KA, et al.
Publicado: (2018)

Expression of OATP Family Members in Hormone-Related Cancers: Potential Markers of Progression
por: Pressler, Heather, et al.
Publicado: (2011)

Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells
por: Novohradsky, Vojtech, et al.
Publicado: (2018)

Correction: Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells
por: Novohradsky, Vojtech, et al.
Publicado: (2018)

Preclinical Studies Comparing Efficacy and Toxicity of DNA Repair Inhibitors, Olaparib, and AsiDNA, in the Treatment of Carboplatin-Resistant Tumors
por: Herath, Nirmitha I., et al.
Publicado: (2019)

Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)
por: Mahdi, Haider, et al.
Publicado: (2021)

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
por: Vasey, P A, et al.
Publicado: (2008)

Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer
por: van der Noll, Ruud, et al.
Publicado: (2015)

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer
por: Rustin, G J, et al.
Publicado: (2010)

Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer
por: Sissung, Tristan M., et al.
Publicado: (2019)

Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells
por: Choi, Young Eun, et al.
Publicado: (2014)

Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib
por: Jain, Lokesh, et al.
Publicado: (2010)

Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study
por: Rosenthal, Mark, et al.
Publicado: (2020)

Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors
por: Lee, Matilda Xinwei, et al.
Publicado: (2022)

SUN-125 Phase Ib Study of Dual Therapy with an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women with Advanced Non-Small Cell Lung Cancer
por: Young, Patricia A, et al.
Publicado: (2020)

Enhanced toxicity to chemoradiation in a patient with Anti-Jo-1-antisynthetase syndrome
por: Valle, Luca, et al.
Publicado: (2022)

FODMAPs—Do they really affect IBS symptoms?
por: Nordin, Elise, et al.
Publicado: (2023)

Olaparib in Epithelial Ovarian Cancer
por: Anastasia, Paula J.
Publicado: (2016)

Olaparib: Transcending mutational barriers
por: Chandna, Abhishek
Publicado: (2019)

Olaparib and somatic BRCA mutations
por: George, Angela, et al.
Publicado: (2017)

Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study
por: Thein, Kyaw Z., et al.
Publicado: (2021)

A SNP in CYP2C8 is not associated with the development of bisphosphonate-related osteonecrosis of the jaw in men with castrate-resistant prostate cancer
por: English, Bevin C, et al.
Publicado: (2010)

Are race-specific ERCC1 haplotypes in melanoma cases versus controls related to the predictive and prognostic value of ERCC1 N118N?
por: Gao, Rui, et al.
Publicado: (2013)

Profile of olaparib in the treatment of advanced ovarian cancer
por: Chase, Dana M, et al.
Publicado: (2016)

Carboplatin binding to histidine
por: Tanley, Simon W. M., et al.
Publicado: (2014)

Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer
por: Jang, Na Young, et al.
Publicado: (2015)

A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial
por: Schouten, Philip C., et al.
Publicado: (2016)

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors
por: Lockhart, A Craig, et al.
Publicado: (2018)

Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients
por: Pastina, Ilaria, et al.
Publicado: (2010)

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells
por: Burgess, Brian T., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ecoq8eslmka1vc4f1k8cdmpdb4